Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion (DEXREDLOS)
Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc
About this trial
This is an interventional treatment trial for Spinal Fusion Acquired focused on measuring Lumbar Fusion, Inflammation, Dexmedetomidine, Length of Hospital Stay, General Anesthesia, Anti-inflammatory, GPCR, Cytokine, Immune Response
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) Classification I - III
- Scheduled for Open Posterior Lumbar Fusion over 3+ (bony) levels
Exclusion Criteria:
- Allergy to dexmedetomidine
- Cardiac disease with reduced ejection fraction < 30%
- History of cirrhosis, active hepatitis or attenuated hepatic function
- Chronic use of steroids, COX-2 inhibitors, alpha-2 agonists, or statins
- Current anticoagulant therapy
- Patients requiring motor evoked potential (MEP) monitoring
- Positive pregnancy test
Sites / Locations
- Vanderbilt University Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Dexmedetomidine
Saline
At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.